Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Abstract

Objective To determine the effects of antiplatelet therapy among patients at high risk of occlusive vascular events.

Remote Assessment of Platelet Function in Patients with Acute Stroke or Transient Ischaemic Attack

“…Antiplatelets are effective at reducing recurrent events after IS or TIA, as shown in multiple large trials and meta-analyses [7–13], and UK guidelines recommend the following antiplatelet regimes (in order): clopidogrel, combined aspirin and dipyridamole, aspirin alone, or dipyridamole alone [14, 15]. In contrast to the use of blood pressure and lipid lowering drugs and anticoagulants, where biomarkers (blood pressure, blood lipids, and coagulation screen) can be used to adjust treatment, antiplatelet drugs are given in a “fire and forget” manner since there are no validated, widely available, or inexpensive tests of platelet function that measure platelet activity reliably and reproducibly, correlate with recurrent events, and can be measured remotely from a dedicated platelet laboratory.…”

Phacoemulsification and intraocular lens implantation for cataract induced by ocular ischemic syndrome: 30-month follow-up

“…9 Antiplatelet therapy has been shown to reduce the incidence of stroke by 25%. 10 Patients with less than 50% stenosis do not benefit from carotid endarterectomy surgery. Most patients with less than 70% stenosis, particularly if they are more than a month from the last symptoms, are probably best treated only medically.…”

The markers of development of aggregation aspirin resistance in patients with coronary heart disease

“…Повышенная агрегационная активность тром-боцитов играет важную роль в патогенезе развития и прогрессирования ИБС. Использование анти-агрегантной терапии для вторичной профилактики у больных, перенесших инфаркт миокарда, обще-признано и подтверждено многочисленными ис-следованиями [4]. В настоящее время «золотым стандартом» антитромбоцитарной терапии призна-на ацетилсалициловая кислота (АСК), которая на протяжении многих лет остается самым назначае-мым антитромбоцитарным препаратом в связи с до-казанной клинической эффективностью и ценовой доступностью [5].…”